AURA vs BIIB Valuation Comparison 2026 — Intrinsic Value Analysis

Quick Summary — BIIB scores higher on quality with 8.4/10 vs AURA's 5.2/10. AURA trades at $6.90 while BIIB trades at $188.83. Both analyzed daily using SEC EDGAR data across 13 institutional models.

AURA

Biological Products, (No Diagnostic Substances)

Aura Biosciences, Inc.

Quality

5.2

out of 10

Value Trap

24

SAFE

Price

$6.90

Last close

Models

9/13

Active

VS

BIIB

Biological Products, (No Diagnostic Substances)

Biogen Inc.

Quality

8.4

out of 10

Value Trap

23

SAFE

Price

$188.83

Last close

Models

13/13

Active

AURA

2 models active

Limited to 2/13 visible models

BIIB

Quality Score 8.4/10 — top tier

Limited to 2/13 visible models

AURA vs BIIB — Fair Value Comparison

AURA

BIIB

Market Price Model 1 Model 2

Model-by-Model Comparison

Model	Type	AURA Fair Value	AURA Upside	BIIB Fair Value	BIIB Upside
Bayesian DCF	Intrinsic	$2.40	-65.3%	$136.51	-27.7%
Earnings Power Value	Intrinsic	—	—	$103.55	-45.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.59	-91.4%	$215.59	+14.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

AURA vs BIIB — Which Stock Is More Undervalued in 2026?

BIIB scores higher with a 8.4/10 quality rating vs AURA's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do AURA and BIIB Valuations Compare?

At $6.90, AURA trades +65.3% above its Bayesian DCF fair value of $2.40, while BIIB at $188.83 trades +27.7% above its estimate of $136.51. AURA shows a wider gap between price and intrinsic value.

Quality of Company: AURA vs BIIB

AURA earns a Quality of Company score of 5.2/10 compared to BIIB's 8.4/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: AURA vs BIIB

AURA carries a SAFE value trap risk (24/100) while BIIB shows SAFE risk (23/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Biological Products, (No Diagnostic Substances)

Both AURA and BIIB operate in Biological Products, (No Diagnostic Substances), which has 6 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare AURA vs BIIB differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

AURA

View Full Aura Biosciences, Inc. Analysis →

BIIB

View Full Biogen Inc. Analysis →